{"id":"https://openalex.org/W2908767342","doi":"https://doi.org/10.3389/fimmu.2018.03120","title":"The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell Carcinoma","display_name":"The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell Carcinoma","publication_year":2019,"publication_date":"2019-01-10","ids":{"openalex":"https://openalex.org/W2908767342","doi":"https://doi.org/10.3389/fimmu.2018.03120","mag":"2908767342","pmid":"https://pubmed.ncbi.nlm.nih.gov/30687324","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6335326"},"language":"en","primary_location":{"id":"doi:10.3389/fimmu.2018.03120","doi":"https://doi.org/10.3389/fimmu.2018.03120","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2018.03120","pdf_url":"https://www.frontiersin.org/articles/10.3389/fimmu.2018.03120/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/articles/10.3389/fimmu.2018.03120/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103952920","display_name":"Asim Amin","orcid":"https://orcid.org/0009-0001-0011-7298","observed_orcids":["https://orcid.org/0009-0001-0011-7298"]},"institutions":[{"id":"https://openalex.org/I4210100342","display_name":"Levine Cancer Institute","ror":"https://ror.org/0174nh398","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334069289","https://openalex.org/I4210100342"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Asim Amin","raw_affiliation_strings":["Atrium Healthcare System, Charlotte, NC, United States","Levine Cancer Institute, Charlotte, NC, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Atrium Healthcare System, Charlotte, NC, United States","institution_ids":[]},{"raw_affiliation_string":"Levine Cancer Institute, Charlotte, NC, United States","institution_ids":["https://openalex.org/I4210100342"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103085920","display_name":"Hans J. Hammers","orcid":"https://orcid.org/0000-0002-6224-4559","observed_orcids":["https://orcid.org/0000-0002-6224-4559"]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hans Hammers","raw_affiliation_strings":["University of Texas Southwestern Medical Center, Dallas, TX, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas Southwestern Medical Center, Dallas, TX, United States","institution_ids":["https://openalex.org/I867280407"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5103952920"],"corresponding_institution_ids":["https://openalex.org/I4210100342"],"apc_list":{"value":2950,"currency":"USD","value_usd":2950},"apc_paid":{"value":2950,"currency":"USD","value_usd":2950},"fwci":1.0488,"has_fulltext":true,"cited_by_count":34,"citation_normalized_percentile":{"value":0.73732913,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"9","issue":null,"first_page":"3120","last_page":"3120"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9375,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9375,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.05900000035762787,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11297","display_name":"Ferroptosis and cancer prognosis","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/advanced-renal-cell-carcinoma","display_name":"advanced renal cell carcinoma","score":0.9959999918937683},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.6669999957084656},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8510000109672546},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9520000219345093},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":1.0},{"id":"https://openalex.org/keywords/vegf-inhibitors","display_name":"VEGF inhibitors","score":0.8889999985694885},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8259999752044678},{"id":"https://openalex.org/keywords/frontline-treatment","display_name":"frontline treatment","score":0.9110000133514404},{"id":"https://openalex.org/keywords/vegf-signaling-pathway","display_name":"VEGF pathway","score":0.7080000042915344},{"id":"https://openalex.org/keywords/dual-immune-checkpoint-inhibition","display_name":"dual immune checkpoint inhibition","score":0.5199999809265137}],"concepts":[{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.9506641626358032},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.9216539859771729},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.8168200254440308},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8121480345726013},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.6227577924728394},{"id":"https://openalex.org/C2777025900","wikidata":"https://www.wikidata.org/wiki/Q29725","display_name":"Vascular endothelial growth factor","level":3,"score":0.6128564476966858},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5396385788917542},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5208954811096191},{"id":"https://openalex.org/C2781068499","wikidata":"https://www.wikidata.org/wiki/Q3242950","display_name":"Kidney cancer","level":3,"score":0.4138544201850891},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.410683810710907},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.36582034826278687},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1926841139793396}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D060908","descriptor_name":"CTLA-4 Antigen","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D060908","descriptor_name":"CTLA-4 Antigen","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.3389/fimmu.2018.03120","doi":"https://doi.org/10.3389/fimmu.2018.03120","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2018.03120","pdf_url":"https://www.frontiersin.org/articles/10.3389/fimmu.2018.03120/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5326691","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/pmc/articles/PMC6335326","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6335326","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6335326","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Immunol","raw_type":"Text"},{"id":"pmid:30687324","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30687324","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in immunology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:c22d07f8c39c4353aedd2e9c82a95e68","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/c22d07f8c39c4353aedd2e9c82a95e68","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Immunology, Vol 9 (2019)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fimmu.2018.03120","doi":"https://doi.org/10.3389/fimmu.2018.03120","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2018.03120","pdf_url":"https://www.frontiersin.org/articles/10.3389/fimmu.2018.03120/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9789000153541565,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2908767342.pdf","grobid_xml":"https://content.openalex.org/works/W2908767342.grobid-xml"},"referenced_works_count":63,"referenced_works":["https://openalex.org/W289544031","https://openalex.org/W795307168","https://openalex.org/W1975831885","https://openalex.org/W1977887541","https://openalex.org/W1986141346","https://openalex.org/W1987446429","https://openalex.org/W1999966467","https://openalex.org/W2004150448","https://openalex.org/W2022540958","https://openalex.org/W2023952988","https://openalex.org/W2024585022","https://openalex.org/W2067969350","https://openalex.org/W2074898491","https://openalex.org/W2088571368","https://openalex.org/W2091463916","https://openalex.org/W2099088585","https://openalex.org/W2118677643","https://openalex.org/W2121820529","https://openalex.org/W2123914905","https://openalex.org/W2129411754","https://openalex.org/W2134131507","https://openalex.org/W2143163879","https://openalex.org/W2148706732","https://openalex.org/W2153867442","https://openalex.org/W2154670252","https://openalex.org/W2155012968","https://openalex.org/W2156906256","https://openalex.org/W2160476851","https://openalex.org/W2162424705","https://openalex.org/W2166662937","https://openalex.org/W2222086386","https://openalex.org/W2237254160","https://openalex.org/W2275872217","https://openalex.org/W2317632169","https://openalex.org/W2322553446","https://openalex.org/W2344221521","https://openalex.org/W2398707058","https://openalex.org/W2543542753","https://openalex.org/W2572174216","https://openalex.org/W2580751003","https://openalex.org/W2611163072","https://openalex.org/W2724506765","https://openalex.org/W2748036232","https://openalex.org/W2764197427","https://openalex.org/W2781513848","https://openalex.org/W2785838318","https://openalex.org/W2790175716","https://openalex.org/W2791328450","https://openalex.org/W2791442381","https://openalex.org/W2791932621","https://openalex.org/W2792937256","https://openalex.org/W2801309958","https://openalex.org/W2810134512","https://openalex.org/W2891290712","https://openalex.org/W2891366395","https://openalex.org/W2892047081","https://openalex.org/W2896903565","https://openalex.org/W2897008012","https://openalex.org/W2897960737","https://openalex.org/W2898436422","https://openalex.org/W2898472087","https://openalex.org/W3001232216","https://openalex.org/W4233481919"],"related_works":["https://openalex.org/W3022153825","https://openalex.org/W2952626531","https://openalex.org/W2805398581","https://openalex.org/W2889311568","https://openalex.org/W2937676990","https://openalex.org/W2902620090","https://openalex.org/W2994968455","https://openalex.org/W2974890594","https://openalex.org/W4281668773","https://openalex.org/W3166096269"],"abstract_inverted_index":{"Insights":[0],"into":[1],"the":[2,11,16,26,33,37,47,55,60,80,98,111,126,137,143],"biology":[3],"of":[4,13,36,62,100],"advanced":[5],"renal":[6,88],"cell":[7,89],"carcinoma":[8,90],"(aRCC)":[9],"and":[10,44,50,54,94,135],"development":[12],"agents":[14],"targeting":[15],"vascular":[17],"endothelial":[18],"growth":[19],"factor":[20],"(VEGF)":[21],"pathway":[22],"have":[23],"positively":[24],"impacted":[25],"outcomes":[27],"for":[28,65,75,87,114,129,142],"patients":[29,76],"with":[30,77,105,119],"aRCC.":[31],"With":[32],"recent":[34],"approval":[35,99],"dual":[38,115],"immune":[39,116],"checkpoint":[40,117],"inhibitors":[41],"(ICIs),":[42],"nivolumab":[43,120],"ipilimumab,":[45],"by":[46],"U.S.":[48],"Food":[49],"Drug":[51],"Administration":[52],"(USFDA),":[53],"European":[56],"Medicines":[57],"Agency":[58],"(EMA),":[59],"era":[61],"VEGF":[63,106,132],"monotherapy":[64],"untreated":[66],"aRCC":[67],"appears":[68],"to":[69,72,79,97],"be":[70],"coming":[71],"an":[73],"end":[74],"access":[78],"combination":[81,102],"therapy.":[82],"The":[83],"frontline":[84],"treatment":[85],"options":[86],"are":[91],"evolving":[92],"rapidly":[93],"will":[95,140],"lead":[96],"other":[101],"immunotherapies-especially":[103],"those":[104],"inhibitors.":[107],"Here":[108],"we":[109],"review":[110],"clinical":[112,144],"data":[113,128],"inhibition":[118],"plus":[121,131],"ipilimumab":[122],"as":[123,125],"well":[124],"emerging":[127],"ICI":[130],"inhibitor":[133],"combinations":[134],"discuss":[136],"challenges":[138],"these":[139],"pose":[141],"practitioner.":[145]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":13},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-01-25T00:00:00"}